Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) reported a substantial revenue increase of 171%, reaching $20.5 million for 2021, driven by its B2B growth and acquisitions. The fourth quarter saw a revenue rise to $6.03 million, a 190% year-on-year increase. However, gross profit as a percentage declined to 9.1%. Operating expenses surged to $22.2 million, leading to an operating loss of $21.7 million. A notable collaboration with Sanofi aims to enhance market presence. Cash reserves stood at $35.8 million, supplemented by a $40 million raise in March 2022 to support ongoing strategic initiatives.

DarioHealth Corp. (Nasdaq: DRIO) will release its financial results for the fourth quarter and full year ended December 31, 2021, on March 21, 2022, post-market close. A conference call will be held on March 22, 2022, at 8:30 am EDT, featuring CEO Erez Raphael and other executives. Participants should join 10 minutes early, with a replay available until April 22, 2022. DarioHealth focuses on digital therapeutics to manage chronic conditions through AI-powered tools and personalized experiences.

DarioHealth Corp. (Nasdaq: DRIO) will participate in the Cowen 42nd Annual Healthcare Conference virtually from March 7-9, 2022. CEO Erez Raphael and President Rick Anderson will hold a fireside chat on March 8 from 11:10-11:40 AM ET. A live webcast will be available here and on their Investor Relations website, with a replay accessible for 90 days. DarioHealth specializes in digital therapeutics, providing solutions for chronic conditions and promoting health improvements through AI-driven, personalized platforms.

DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic agreement with Sanofi U.S., valued at $30 million. This multi-year contract aims to enhance the commercial adoption of Dario's digital therapeutics and expand digital health solutions on its platform. The collaboration will significantly increase Dario's market reach in health plans and employers. Dario will leverage its comprehensive digital therapeutics to help manage chronic conditions, aligning with Sanofi’s goal to integrate healthcare and technology for chronic disease management.

DarioHealth Corp. (Nasdaq: DRIO) announced a registered direct offering on February 28, 2022, with institutional investors, raising approximately $40 million. The sale includes about 5.34 million shares priced at $7.49 each, along with pre-funded warrants. The proceeds will support the expansion of its digital health platform in the U.S. market and further development of new solutions. The offering is expected to close by March 3, 2022. It is conducted under a shelf registration statement with the SEC, ensuring compliance with securities laws.

DarioHealth Corp. (Nasdaq: DRIO) announced a study published in the Journal of Medical Internet Research highlighting the effectiveness of its integrated digital therapeutics platform in managing both diabetes and hypertension. The study revealed that users managing both conditions saw a significant reduction in average blood glucose and blood pressure levels, with 27% achieving more than a 10mmHg systolic blood pressure reduction. Dario emphasizes the importance of a holistic approach to chronic condition management and aims to lead in integrated health solutions.

DarioHealth Corp. (Nasdaq: DRIO) announced an agreement to acquire assets from Physimax Technologies Ltd., specializing in computer vision technology for musculoskeletal screening. This technology, used by organizations like the NBA and U.S. military, offers automated injury assessments and personalized training programs. The acquisition involves issuing up to 256,660 shares and a cash payment of $500,000, alongside assuming liabilities of approximately $1,020,000. DarioHealth aims to enhance its offerings, promoting growth in musculoskeletal health care while reducing reliance on human support.